Xenon (XENE) | Financial Analysis & Statements
Xenon Pharmaceuticals Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-109.8M
Net Income
-105.3M
EPS (Diluted)
$-1.31
Balance Sheet Metrics
Total Assets
633.2M
Total Liabilities
51.4M
Shareholders Equity
581.8M
Debt to Equity
0.09
Cash Flow Metrics
Operating Cash Flow
-89.0M
Free Cash Flow
-81.8M
Revenue & Profitability Trend
Annual Income Flow
2025
Xenon Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 7.5M | 0 | 0 | 9.4M | 18.4M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 300.9M | 210.4M | 167.5M | 105.8M | 75.5M |
| Selling, General & Administrative | 79.6M | 68.9M | 46.5M | 32.8M | 22.0M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 380.6M | 279.3M | 214.1M | 138.6M | 97.4M |
| Operating Income | -373.1M | -279.3M | -214.1M | -129.1M | -79.0M |
| Operating Margin % | -4,974.3% | 0.0% | 0.0% | -1,368.9% | -428.4% |
| Non-Operating Items | |||||
| Interest Income | 26.8M | 41.9M | 27.6M | 8.7M | 466.0K |
| Interest Expense | - | - | - | 0 | 0 |
| Other Non-Operating Income | 1.3M | -1.1M | 3.7M | -4.8M | -361.0K |
| Pre-tax Income | -344.9M | -238.4M | -182.7M | -125.3M | -78.9M |
| Income Tax | 1.0M | -4.1M | -292.0K | 118.0K | -6.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -345.9M | -234.3M | -182.4M | -125.4M | -78.9M |
| Net Margin % | -4,612.1% | 0.0% | 0.0% | -1,328.9% | -427.8% |
| Key Metrics | |||||
| EBITDA | -371.9M | -275.7M | -214.3M | -122.7M | -77.7M |
| EPS (Basic) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 |
| EPS (Diluted) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 |
| Basic Shares Outstanding | 79253751 | 77894643 | 66889005 | 60542142 | 43627452 |
| Diluted Shares Outstanding | 79253751 | 77894643 | 66889005 | 60542142 | 43627452 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Xenon Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 199.2M | 142.7M | 148.6M | 57.2M | 175.7M |
| Short-term Investments | 349.7M | 484.2M | 489.4M | 534.8M | 376.1M |
| Accounts Receivable | 1.4M | 1.5M | 874.0K | 986.0K | 2.8M |
| Inventory | - | - | - | - | - |
| Other Current Assets | 10.4M | 6.9M | 6.0M | 7.2M | 4.5M |
| Total Current Assets | 560.6M | 635.3M | 645.0M | 600.3M | 559.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 12.1M | 11.6M | 9.1M | 8.9M | 8.4M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 12.9M | 9.7M | 802.0K | 509.0K | 465.0K |
| Total Non-Current Assets | 72.5M | 162.9M | 319.8M | 153.8M | 13.0M |
| Total Assets | 633.2M | 798.1M | 964.8M | 754.1M | 572.0M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 3.9M | 5.1M | 8.6M | 8.5M | 3.8M |
| Short-term Debt | 1.5M | 1.4M | 1.3M | 488.0K | 605.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 41.8M | 35.6M | 27.3M | 22.7M | 14.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 6.4M | 7.6M | 9.6M | 9.9M | 7.7M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 3.2M | - | - | - | - |
| Total Non-Current Liabilities | 9.6M | 7.6M | 9.6M | 9.9M | 7.7M |
| Total Liabilities | 51.4M | 43.2M | 36.9M | 32.6M | 22.0M |
| Equity | |||||
| Common Stock | 1.6B | 1.5B | 1.4B | 1.1B | 783.2M |
| Retained Earnings | -1.2B | -899.5M | -665.1M | -482.7M | -357.4M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 581.8M | 754.9M | 927.9M | 721.5M | 550.0M |
| Key Metrics | |||||
| Total Debt | 7.9M | 9.0M | 10.9M | 10.4M | 8.3M |
| Working Capital | 518.9M | 599.7M | 617.7M | 577.6M | 544.7M |
Balance Sheet Composition
Xenon Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -345.9M | -234.3M | -182.4M | -125.4M | -78.9M |
| Depreciation & Amortization | 2.5M | 2.6M | 3.5M | 1.6M | 906.0K |
| Stock-Based Compensation | 53.7M | 50.7M | 32.4M | 20.4M | 10.0M |
| Working Capital Changes | 2.0M | -1.8M | 130.0K | 1.8M | -4.1M |
| Operating Cash Flow | -289.5M | -190.5M | -146.6M | -101.7M | -72.0M |
| Investing Activities | |||||
| Capital Expenditures | -799.0K | -3.1M | -5.6M | -2.9M | -2.0M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -355.7M | -532.3M | -793.9M | -551.1M | -389.5M |
| Investment Sales | 574.5M | 700.3M | 682.4M | 258.0M | 144.8M |
| Investing Cash Flow | 218.0M | 165.0M | -117.2M | -296.0M | -246.8M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | 0 | 0 |
| Financing Cash Flow | 112.2M | 12.1M | 353.5M | 277.8M | 447.3M |
| Free Cash Flow | -279.9M | -184.5M | -150.9M | -101.3M | -71.6M |
| Net Change in Cash | 40.6M | -13.4M | 89.7M | -119.9M | 128.5M |
Cash Flow Trend
Xenon Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-12.66
Forward P/E
-11.71
Price to Book
7.62
Price to Sales
714.00
PEG Ratio
-0.23
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-4,974.27%
Return on Equity
-51.76%
Return on Assets
-32.58%
Financial Health
Current Ratio
13.42
Debt to Equity
1.37
Beta
0.74
Per Share Data
EPS (TTM)
$-4.36
Book Value per Share
$7.27
Revenue per Share
$0.10
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| XENE | 5.3B | -12.66 | 7.62 | -51.76% | 0.00% | 1.37 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






